VANCOUVER, BC — August 13, 2025 — Leads & Copy — Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) has announced the closure of its non-brokered private placement, initially disclosed on July 29, 2025. The placement involved 243,903 units at $1.64 each, raising $400,000. Each unit includes one common share and a warrant, exercisable at $2.05 until August 13, 2028.
The company intends to use the proceeds for general corporate purposes, research, and development. Additionally, 2,439 administrative shares were issued for services related to the placement. All securities are subject to a four-month hold, expiring December 14, 2025. These securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the U.S. without registration or exemption.
Onco-Innovations specializes in cancer research and treatment, holding an exclusive license for a patented technology targeting solid tumors.
Thomas O’Shaughnessy, CEO, can be reached at + 1 888 261 8055 or investors@oncoinnovations.com.
Source: Onco-Innovations Limited
